2011 Innovative Product Award

Boehringer Ingelheim (Canada) Ltd.
Dabigatran etexilate
Pradax

The Prix Galien Canada 2011 Innovative Product Award is presented to Pradax (dabigatran etexilate) marketed by Boehringer Ingelheim (Canada) Ltd.

Pradax (dabigatran etexilate) is a direct thrombin inhibitor. It acts by binding directly to the catalytic site of thrombin. It is the first of the new oral agents to be approved in Canada for use in both venous thromboembolic events and prevention of stroke in patients with atrial fibrillation. It offers an alternative to patients with atrial fibrillation who cannot use vitamin K antagonists.

The Prix Galien Canada Innovative Product Award is presented to a drug on the Canadian market judged by the jury to have the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits and innovation.